Regulatory Sourcebook eBook
Read the article:
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices
Read the ebook:
Pharmaceutical Technology Regulatory Sourcebook eBook
News|Articles|September 15, 2021
- Pharmaceutical Technology, Regulatory Sourcebook, September 2021
- Volume 2021 eBook
- Issue 3
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices
Author(s)Chris Burgess
Inconsistent sampling and testing processes can lead to errors, resulting in data integrity issues and potentially incorrect decisions about pharmaceutical quality.
Advertisement
In pharma applications, consistent sampling and testing nomenclature is critical for data integrity and compliance with specifications and regulatory standards. Inconsistent sampling and testing processes can lead to errors, resulting in data integrity issues and potentially incorrect decisions about pharmaceutical quality.
Guidance documents within the pharma industry and other regulated sectors, however, offer conflicting information. This review of regulatory and compendial standards reveals the scope of the problem.
This article provides a review of available analytical nomenclature, recommended naming for individual steps, and terms used in the process flows. Part two of this paper proposes a simplified approach for sampling and testing nomenclature.
About the author
Chris Burgess is managing director, Burgess Analytical Consultancy Limited, Barnard Castle, Co Durham, UK.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook
September 2021
Pages: 23–33
Citation
When referring to this article, please cite it as C. Burgess, “Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices," Pharmaceutical Technology Regulatory Sourcebook eBook (September 2021).
Articles in this issue
about 5 years ago
Understanding Combination Product Regulationsabout 5 years ago
Considering Titanium Dioxide Regulatory Changesabout 5 years ago
The Real Danger of Substandard and Counterfeit COVID-19 Vaccinesabout 5 years ago
Changing the Course of Drug Shortagesabout 5 years ago
Industry Organizations Assist Pharma During the Pandemic and Beyondabout 5 years ago
Mapping Out Pharma’s Regulatory Future in EuropeAdvertisement
Related to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
5